Apollo Hospitals Enterprise working capital

Profitability Growth Credit Liquidity Working capital Dividend yield DuPont CAGR

Per cent unless marked ×

Tap a line for its trend	Last 12Mto Jun 2026	FY26Mar 2026	FY25Mar 2025	FY24Mar 2024	FY23Mar 2023	FY22 and earlierAlpha Plus

14.28×	14.28×	15.18×	15.82×	17.50×	FY22 and earlierEvery year the company has filed comes with Alpha Plus.
47.03×	47.03×	46.32×	45.47×	43.96×
62.70×	62.70×	74.37×	79.74×	75.51×
−1.39×	−1.39×	−12.87×	−18.45×	−14.05×
63.15×	60.28×	8.90×	30.98×	16.41×
1.18×	1.18×	1.17×	1.22×	1.20×
1.43×	1.43×	1.42×	2.05×	1.63×
0.76×	0.76×	0.71×	0.80×	0.67×

Open the chart

From the company's filings with NSE and BSE (Ind-AS), consolidated. For information only, not investment advice.

alphave

APOLLOHOSP₹8,200.00

Apollo Hospitals Enterprise Ltd.

· Pharma & Health

₹ CrorePeersFORTIS MAXHEALTH MEDANTA SUNPHARMA CIPLA DRREDDY DIVISLAB TORNTPHARMMcap ₹1.18L Cr

Profitability Growth Credit Liquidity Working Capital Yield Analysis DuPont

Ratios — % unless marked × 12 Months Ending	FY23 31/03/2023	FY24 31/03/2024	FY25 31/03/2025	FY26 31/03/2026	Last 12M 30/06/2026
Inventory Days (DIO)	17.50	15.82	15.18	14.28	14.28
Receivable Days (DSO)	43.96	45.47	46.32	47.03	47.03
Payable Days (DPO)	75.51	79.74	74.37	62.70	62.70
Cash Conversion Cycle (days)	-14.05	-18.45	-12.87	-1.39	-1.39
Working Capital Turnover	16.41	30.98	8.90	60.28	63.15
Asset Turnover	1.20	1.22	1.17	1.18	1.18
Cash Conversion (CFO/Net Income)	1.63	2.05	1.42	1.43	1.43
CFO/EBITDA	0.67	0.80	0.71	0.76	0.76

No consensus estimates → no Est columns. Click any row to chart it.

« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave

Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 145%.